| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Specific molecular targets for (E)-5-O-Cinnamoylquinic acid are not well characterized in the literature. As a phenolic compound, it is expected to interact with oxidative stress-related pathways and may modulate the activity of enzymes such as cyclooxygenases (COX) or lipoxygenases (LOX) involved in inflammation. It may also interact with nuclear factor-kappa B (NF-κB) and other transcription factors involved in inflammatory responses. The compound's antioxidant activity is likely mediated through direct radical scavenging.
|
|---|---|
| ln Vitro |
In vitro activity data for (E)-5-O-Cinnamoylquinic acid are limited. As a cinnamoylquinic acid derivative, it is expected to exhibit antioxidant activity through DPPH and ABTS radical scavenging assays. It may also show anti-inflammatory activity by inhibiting the production of pro-inflammatory mediators such as nitric oxide, prostaglandins, and cytokines in activated macrophages. Specific IC₅₀ values and detailed activity profiles are not extensively documented.
|
| ln Vivo |
In vivo activity data for (E)-5-O-Cinnamoylquinic acid are not extensively documented. Based on its in vitro antioxidant and anti-inflammatory activities, it is anticipated to have potential in vivo efficacy in models of oxidative stress and inflammation. However, specific animal studies detailing its therapeutic effects, dosing, and pharmacokinetics are limited.
|
| Enzyme Assay |
The non-cellular enzyme/receptor binding assays for (E)-5-O-Cinnamoylquinic acid would typically involve antioxidant activity evaluation using chemical assays such as DPPH, ABTS, and FRAP. The compound's ability to scavenge free radicals is measured spectrophotometrically. Anti-inflammatory activity can be assessed using enzyme inhibition assays for COX-1, COX-2, and LOX enzymes. The compound is incubated with the enzyme and substrate, and the inhibition of product formation is measured. IC₅₀ values are calculated.
|
| Cell Assay |
In vitro cellular assays for (E)-5-O-Cinnamoylquinic acid typically use macrophage cell lines such as RAW 264.7 to evaluate anti-inflammatory activity. Cells are treated with various concentrations of the compound, followed by stimulation with lipopolysaccharide (LPS) to induce inflammation. Nitric oxide production is measured using the Griess assay. Pro-inflammatory cytokine levels (TNF-α, IL-1β, IL-6) are quantified by ELISA. Cell viability is assessed using MTT assays to ensure observed effects are not due to cytotoxicity.
|
| Animal Protocol |
In vivo animal studies for (E)-5-O-Cinnamoylquinic acid are not extensively documented. Based on its potential anti-inflammatory activity, typical study designs would involve rodent models of inflammation such as carrageenan-induced paw edema or LPS-induced systemic inflammation. The compound would be administered orally or intraperitoneally. Inflammatory markers in blood and tissues, as well as histopathological changes, would be evaluated.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of (E)-5-O-Cinnamoylquinic acid are not characterized in the literature. As a polar phenolic compound with multiple hydroxyl groups, it is expected to have limited oral bioavailability due to poor membrane permeability and extensive first-pass metabolism. Metabolic pathways likely involve phase II conjugation (glucuronidation and sulfation) and possibly phase I hydrolysis of the ester bond. Specific PK parameters are not documented.
|
| Toxicity/Toxicokinetics |
Toxicological data for (E)-5-O-Cinnamoylquinic acid are limited. As a naturally occurring phenolic compound, it is generally considered to have low toxicity. However, comprehensive toxicology studies are not available. The compound may cause skin and eye irritation upon contact. Standard laboratory safety precautions should be observed when handling this compound.
|
| References | |
| Additional Infomation |
(E)-5-O-Cinnamoylquinic acid is a research-grade natural product intended for laboratory use only. It is not approved for clinical use as a therapeutic agent. Its primary applications include natural product chemistry research, phytochemical analysis, and studies on the antioxidant and anti-inflammatory activities of plant-derived compounds. It serves as a reference standard for the identification and quantification of cinnamoylquinic acid derivatives in plant extracts.
|
| Molecular Formula |
C16H18O7
|
|---|---|
| Molecular Weight |
322.309925556183
|
| Exact Mass |
322.105
|
| CAS # |
6470-68-4
|
| Related CAS # |
5-O-Cinnamoylquinic acid;5515-82-2
|
| PubChem CID |
24094125
|
| Appearance |
White to off-white solid powder
|
| Density |
1.45±0.1 g/cm3 at 760 mmHg
|
| Boiling Point |
566.5±50.0 °C at 760 mmHg
|
| LogP |
0.3
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
23
|
| Complexity |
469
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1[C@H]([C@@H]([C@@H](C[C@]1(C(=O)O)O)OC(=O)/C=C/C2=CC=CC=C2)O)O
|
| InChi Key |
WTMHIVNZOSRKJU-VIUXVBALSA-N
|
| InChi Code |
InChI=1S/C16H18O7/c17-11-8-16(22,15(20)21)9-12(14(11)19)23-13(18)7-6-10-4-2-1-3-5-10/h1-7,11-12,14,17,19,22H,8-9H2,(H,20,21)/b7-6+/t11-,12-,14+,16-/m1/s1
|
| Chemical Name |
(1R,3R,4S,5R)-1,3,4-trihydroxy-5-[(E)-3-phenylprop-2-enoyl]oxycyclohexane-1-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1026 mL | 15.5130 mL | 31.0260 mL | |
| 5 mM | 0.6205 mL | 3.1026 mL | 6.2052 mL | |
| 10 mM | 0.3103 mL | 1.5513 mL | 3.1026 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
